703,865 Shares in Agios Pharmaceuticals, Inc. $AGIO Purchased by Capital International Investors

Posted by Geri Gentry on Jun 10th, 2026

Capital International Investors purchased a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) during the fourth quarter, Holdings Channel reports. The firm purchased 703,865 shares of the biopharmaceutical company’s stock, valued at approximately $19,159,000.

Other hedge funds also recently bought and sold shares of the company. Assetmark Inc. boosted its position in Agios Pharmaceuticals by 37.9% during the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 362 shares in the last quarter. NewEdge Advisors LLC purchased a new position in Agios Pharmaceuticals during the first quarter worth approximately $40,000. Quantbot Technologies LP purchased a new position in Agios Pharmaceuticals during the third quarter worth approximately $79,000. Eurizon Capital SGR S.p.A. purchased a new position in Agios Pharmaceuticals during the fourth quarter worth approximately $72,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Agios Pharmaceuticals by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 588 shares in the last quarter.

Insider Transactions at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 3,141 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $109,024.11. Following the transaction, the chief financial officer owned 54,998 shares in the company, valued at $1,908,980.58. This trade represents a 5.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sarah Gheuens sold 2,940 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $102,047.40. Following the completion of the transaction, the insider owned 80,277 shares in the company, valued at approximately $2,786,414.67. This trade represents a 3.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 12,623 shares of company stock worth $438,144. 5.40% of the stock is owned by insiders.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $28.14 on Wednesday. The company has a market cap of $1.67 billion, a PE ratio of -3.88 and a beta of 0.59. The stock’s 50 day simple moving average is $29.55 and its 200-day simple moving average is $28.43. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, beating the consensus estimate of ($1.81) by $0.12. The business had revenue of $20.75 million for the quarter, compared to the consensus estimate of $13.30 million. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The company’s revenue for the quarter was up 137.7% on a year-over-year basis. On average, equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AGIO has been the topic of a number of recent analyst reports. HC Wainwright lowered their price target on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Citigroup increased their price target on Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Bank of America lowered their price target on Agios Pharmaceuticals from $41.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, May 29th. Truist Financial lowered their price target on Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, April 30th. Finally, The Goldman Sachs Group increased their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 1st. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Agios Pharmaceuticals has an average rating of “Hold” and an average price target of $41.44.

Check Out Our Latest Research Report on AGIO

Agios Pharmaceuticals Profile

(Free Report)

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.